Carlisle Companies Incorporated (CSL)

On 27 June 2026, Carlisle Companies Incorporated (NYSE: CSL) was removed from the Russell 1000 Defensive, Russell 1000 Value-Defensive, and Russell 1000 Growth-Defensive indices, prompting rebalancing by index-tracking funds. This simultaneous exit from multiple Russell 1000 defensive-style ...

CSL Ltd (AU000000CSL8) remains one of Australia's best-known healthcare groups, with operations tied to plasma therapies, specialty medicines and vaccine-related work. The stock trades on the ASX and fits a global investor base that follows both execution and product mix. CSL's earnings profile ...

CSL's strategy focuses on expanding plasma collections, improving production efficiency, advancing its research pipeline and integrating acquired businesses to strengthen future earnings growth. The company also continues to invest in innovation, including new therapies, vaccine technologies and pro…

Carlisle Companies (CSL) has been removed from the Russell 1000 Value Defensive, Growth Defensive, and Defensive indices, a shift that may prompt index-tracking funds to adjust positions and influence short term trading flows. See our latest analysis for Carlisle Companies.

Carlisle Companies (NYSE:CSL) was dropped from three Russell 1000 indices: Value Defensive, Defensive, and Growth Defensive, effective June 27, 2026. The change alters Carlisle's index footprint, which can influence passive fund ownership and how the stock is grouped with defensive or growth peers.